teaser
UK biotech company Amgen is acquiring the rights to Cytokinetics’s experimental heart drug CK-1827452 at present being trialled for the treatment of heart failure.
Amgen will pay $50 million (£31.6m) upfront and up to $600 million in the future, depending on the drug’s success. CK-1827452 is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Amgen had earlier paid $75m for the option to the drug, and decided to exercise the option after seeing more clinical data, according to the New York Times.
Copyright Press Association 2009
